ARQT Quote, Financials, Valuation and Earnings

Alnylam Pharmaceuticals has a net margin of -38.06% compared to Arcutis Biotherapeutics's net margin of -9.67%. Arcutis Biotherapeutics's return on equity of -74.7% beat Alnylam Pharmaceuticals's return on equity of --.

Arcutis Biotherapeutics has a consensus price target of $21.14, signalling upside risk potential of 53.66%. On the other hand Alnylam Pharmaceuticals has an analysts' consensus of $325.06 which suggests that it could fall by -1.43%. Given that Arcutis Biotherapeutics has higher upside potential than Alnylam Pharmaceuticals, analysts believe Arcutis Biotherapeutics is more attractive than Alnylam Pharmaceuticals.

Arcutis Biotherapeutics has a beta of 1.767, which suggesting that the stock is 76.661% more volatile than S&P 500. In comparison Alnylam Pharmaceuticals has a beta of 0.226, suggesting its less volatile than the S&P 500 by 77.386%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Alnylam Pharmaceuticals pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $65.8M, which are smaller than Alnylam Pharmaceuticals quarterly revenues of $594.2M. Arcutis Biotherapeutics's net income of -$25.1M is higher than Alnylam Pharmaceuticals's net income of -$57.5M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Alnylam Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 8.06x versus 18.05x for Alnylam Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ardelyx has a net margin of -38.06% compared to Arcutis Biotherapeutics's net margin of -55.52%. Arcutis Biotherapeutics's return on equity of -74.7% beat Ardelyx's return on equity of -34.68%.

Arcutis Biotherapeutics has a consensus price target of $21.14, signalling upside risk potential of 53.66%. On the other hand Ardelyx has an analysts' consensus of $10.73 which suggests that it could grow by 156.02%. Given that Ardelyx has higher upside potential than Arcutis Biotherapeutics, analysts believe Ardelyx is more attractive than Arcutis Biotherapeutics.

Arcutis Biotherapeutics has a beta of 1.767, which suggesting that the stock is 76.661% more volatile than S&P 500. In comparison Ardelyx has a beta of 0.605, suggesting its less volatile than the S&P 500 by 39.538%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ardelyx offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Ardelyx pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $65.8M, which are smaller than Ardelyx quarterly revenues of $74.1M. Arcutis Biotherapeutics's net income of -$25.1M is higher than Ardelyx's net income of -$41.1M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Ardelyx's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 8.06x versus 2.74x for Ardelyx. Usually stocks with elevated PS ratios are considered overvalued.

Blueprint Medicines has a net margin of -38.06% compared to Arcutis Biotherapeutics's net margin of 0.33%. Arcutis Biotherapeutics's return on equity of -74.7% beat Blueprint Medicines's return on equity of -49.13%.

Arcutis Biotherapeutics has a consensus price target of $21.14, signalling upside risk potential of 53.66%. On the other hand Blueprint Medicines has an analysts' consensus of $126.87 which suggests that it could fall by -1.04%. Given that Arcutis Biotherapeutics has higher upside potential than Blueprint Medicines, analysts believe Arcutis Biotherapeutics is more attractive than Blueprint Medicines.

Arcutis Biotherapeutics has a beta of 1.767, which suggesting that the stock is 76.661% more volatile than S&P 500. In comparison Blueprint Medicines has a beta of 0.894, suggesting its less volatile than the S&P 500 by 10.564%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Blueprint Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. Blueprint Medicines pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $65.8M, which are smaller than Blueprint Medicines quarterly revenues of $149.4M. Arcutis Biotherapeutics's net income of -$25.1M is lower than Blueprint Medicines's net income of $496K. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while Blueprint Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 8.06x versus 14.62x for Blueprint Medicines. Usually stocks with elevated PS ratios are considered overvalued.

TG Therapeutics has a net margin of -38.06% compared to Arcutis Biotherapeutics's net margin of 4.19%. Arcutis Biotherapeutics's return on equity of -74.7% beat TG Therapeutics's return on equity of 19.78%.

Arcutis Biotherapeutics has a consensus price target of $21.14, signalling upside risk potential of 53.66%. On the other hand TG Therapeutics has an analysts' consensus of $41.20 which suggests that it could grow by 13.53%. Given that Arcutis Biotherapeutics has higher upside potential than TG Therapeutics, analysts believe Arcutis Biotherapeutics is more attractive than TG Therapeutics.

Arcutis Biotherapeutics has a beta of 1.767, which suggesting that the stock is 76.661% more volatile than S&P 500. In comparison TG Therapeutics has a beta of 1.913, suggesting its more volatile than the S&P 500 by 91.257%.

Arcutis Biotherapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TG Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Arcutis Biotherapeutics pays -- of its earnings as a dividend. TG Therapeutics pays out -- of its earnings as a dividend.

Arcutis Biotherapeutics quarterly revenues are $65.8M, which are smaller than TG Therapeutics quarterly revenues of $120.9M. Arcutis Biotherapeutics's net income of -$25.1M is lower than TG Therapeutics's net income of $5.1M. Notably, Arcutis Biotherapeutics's price-to-earnings ratio is -- while TG Therapeutics's PE ratio is 151.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Arcutis Biotherapeutics is 8.06x versus 15.10x for TG Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.